目的: 满足人民群众优医优药的需求,为我国创新药医保准入与定价程序优化提供参考。方法: 从决策机构、决策流程、决策标准三个维度系统梳理瑞士的创新药准入与定价政策,对标我国当前的政策现状,分析存在的问题与不足。结果: 瑞士通过以“WWZ”为核心的卫生技术评估程序严格审查申请准入的药品,在定价方面也综合了内部和外部参考价格保证价格的合理性,并且为鼓励创新,创新药还可获得高于对照药品的“创新溢价”。结论: 完善药品卫生技术评估制度,结合评估结果给予不同创新程度的药品差异化的价格或者报销水平,同时更加注重与多方利益相关者的沟通,促进其参与到相关的决策之中,保证评审工作的公开透明。
Abstract
Objective: To meet the people's demand for excellent medicine, the paper provides reference for the optimization of medical insurance access and pricing procedures for innovative drugs in China. Methods: This paper systematically summarizes the access and pricing policies of innovative drugs in Switzerland from three dimensions: decision-making institutions, processes and standards, and analyzes the problems and shortcomings of the current policy in China. Results: Switzerland strictly examines the drugs applying for access through the health technology assessment procedure with “WWZ” as the core, and integrates the internal and external reference prices to ensure the rationality of the price. In order to encourage innovation, innovative drugs can also get an "innovation premium" higher than the reference drugs. Conclusion: We should improve the drug health technology assessment system, and give different prices or reimbursement rates to drugs with different degrees of innovation according to the evaluation results. At the same time, we should pay attention to the communication with multiple stakeholders, promote their participation in decision-making, and ensure the openness and transparency of the evaluation.
关键词
瑞士 /
创新药 /
医保准入 /
药品定价
Key words
Switzerland /
innovative drugs /
medical insurance access /
drug pricing
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 中国外商投资企业协会药品研制和开发行业委员会与财新智库.以高水平开放推动中国医药创新蓝皮书[EB/OL].(2022-11-04)[2023-10-10].http://www.rdpac.org/index.php?r=site%2Fresource.
[2] JNSSON B, HOFMARCHER T, LINDGREN P, et al.Comparator report on patient access to cancer medicines in Europe revisited[J].2016.
[3] 庞岩,丁锦希,李伟,等.瑞士医疗保险风险调剂金制度对我国的启示[J].卫生软科学,2022,36(6):93-96.
[4] DE PIETRO C, CAMENZIND P, STURNY I, et al.Switzerland: health system review[J].Health systems in transition.2015, 17(4):1-288.
[5] 邓绍平,钟若冰.全保险制度下的瑞士医疗体系[J].医院领导决策参考,2011(18):4.
[6] Federal Office of Public Health.Health insurance: premiums and co-payment[EB/OL].(2023-03-14)[2023-10-12].https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-versicherte-mit-wohnsitz-in-der-schweiz/praemien-kostenbeteiligung.html.
[7] Federal Office of Public Health.The compulsory health insurance system(guide)[EB/OL].(2023-09-29)[2023-10-12].https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-das-wichtigste-in-kuerze.html.
[8] Paris, Valérie, Docteur, et al.Pharmaceutical pricing and reimbursement policies in switzerland[J].OECD papers, 2007.
[9] Interpharma.The authorisation and reimbursement process[EB/OL].(2023-03-30)[2024-12-20].https://www.interpharma.ch/themen/der-patient-im-mittelpunkt/patientenzugang/bag-verguetungsprozess/?lang=en.
[10] Federal Office of Public Health.HTA-Programm[EB/OL].(2023-01-06)[2023-10-12].https://www.bag.admin.ch/bag/de/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-programm.html.
[11] Swissmedic.HTA programme[EB/OL].(2023-07-21)[2023-10-20].https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-programm.html.
[12] 张天问,张奥,郭思琦,等.创新药新增适应症的医保准入国际经验研究[J].中国医疗保险,2022,(12):116-121.
[13] Hunkeler, 2006, Rapport écrit du Conseil Fédéraldu 2 décembre 1996, Compte rendu de la Session parlementaire de l'été 2002, dixième séance ; Rapports annuels de la Surveillance des prix 1996, 1997, 2001, OFSP, Communiqué de presse du 13 septembre 2005.
[14] CMS LAW-NOW.Pricing of Medicines in Switzerland | Three-yearly price review: what are the most important changes for 2023?[EB/OL].(2023-01-24)[2023-10-20].https://cms-lawnow.com/en/ealerts/2023/01/pricing-of-medicines-in-switzerland-three-yearly-price-review-what-are-the-most-important-changes-for-2023.
[15] Global Legal Insights.Pricing and Reimbursement Laws and Regulations2022 | Switzerland[EB/OL].(2023-01-01)[2023-10-20].https://www.globallegalinsights.com/practice-areas/pricing-and-reimbursement-laws-and-regulations/switzerland.
[16] 郑王彪,郑超,孙强.医保药品目录动态调整的国际经验与启示[J].卫生经济研究,2023,40(12):62-67.
[17] 李灵玉,王聪,陈忠兰,等.国外普适性卫生技术评估工具分析及对我国的启示[J].中国卫生质量管理,2023,30(04):76-81.
[18] 金秋晨,李梦颖,陈永法.英国NICE卫生技术评估公众参与机制及启示[J].中国药房,2023,34(11):1302-1306.
[19] 姚雯,颜建周,邵蓉.典型国家创新药医保谈判准入评价标准研究及对我国的启示[J].中国新药杂志,2021,30(12):6.
[20] 颜建周,李大双,任晓悦,等.创新药医保准入差异化管理国际经验及启示[J].中国医疗保险,2023(01):5-11.
基金
医疗卫生系统价值医疗体系研究项目（WH10022023001）
